Skip to main content

ABBOTT LABORATORIES

For the period ended Dec 31, 2024. Filed Feb 21, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 21, 2025

ABT$110.51+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statement of Earnings

(in millions except per share data)

Year Ended December 31
202420232022
Net Sales$41,950$40,109$43,653
Cost of products sold, excluding amortization of intangible assets18,70617,97519,142
Amortization of intangible assets1,8781,9662,013
Research and development2,8442,7412,888
Selling, general and administrative11,69710,94911,248
Total Operating Cost and Expenses35,12533,63135,291
Operating Earnings6,8256,4788,362
Interest expense559637558
Interest income(344)(385)(183)
Net foreign exchange (gain) loss(27)412
Other (income) expense, net(376)(479)(321)
Earnings before Taxes7,0136,6648,306
Taxes on Earnings(6,389)9411,373
Net Earnings$13,402$5,723$6,933
Basic Earnings Per Common Share$7.67$3.28$3.94
Diluted Earnings Per Common Share$7.64$3.26$3.91
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share1,7401,7401,753
Dilutive Common Stock Options8911
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,7481,7491,764
Outstanding Common Stock Options Having No Dilutive Effect753
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.